Literature DB >> 19050412

Variability of the in vivo metabolism of clozapine.

Thomas J Raedler1, Kim Hinkelmann, Klaus Wiedemann.   

Abstract

OBJECTIVES: Clozapine, the gold standard of antipsychotic treatment in treatment-refractory patients with schizophrenia, is metabolized in vivo to clozapine-N-oxide and N-desmethylclozapine (NDMC = norclozapine). N-desmethylclozapine is an active metabolite of clozapine and combines unique pharmacological properties. Because little is known about the rate of metabolic conversion of clozapine in vivo, we assessed the association between clozapine dose and plasma levels for clozapine and NDMC.
METHODS: Plasma levels of clozapine and NDMC were measured in 485 blood samples from 108 patients with schizophrenia treated with clozapine. %NDMC, the ratio of NDMC to total clozapine (NDMC + clozapine), was used as a measure of the in vivo metabolism of clozapine.
RESULTS: Daily clozapine doses correlated significantly with clozapine levels and NDMC levels, whereas %NDMC showed a weaker negative correlation with clozapine dose. The mean %NDMC value was 37.0% +/- 16.8%, with high variability between subjects. Repeated measurements in subjects treated with the same dose of clozapine showed a high within-subject variability of %NDMC.
CONCLUSIONS: Our results suggest a high degree of between-subject and within-subject variability in the metabolism of clozapine in vivo. Direct administration of NDMC may be preferable to reliably achieve sufficient plasma levels of this compound.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050412     DOI: 10.1097/WNF.0b013e31815cba61

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

1.  Can valproic acid be an inducer of clozapine metabolism?

Authors:  F J Diaz; C B Eap; N Ansermot; S Crettol; E Spina; J de Leon
Journal:  Pharmacopsychiatry       Date:  2014-04-24       Impact factor: 5.788

Review 2.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

3.  Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.

Authors:  Kathryn K Erickson-Ridout; Dongxiao Sun; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

4.  Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics.

Authors:  Claire H Li; Robert E Stratford; Nieves Velez de Mendizabal; Thomas I F H Cremers; Bruce G Pollock; Benoit H Mulsant; Gary Remington; Robert R Bies
Journal:  J Transl Med       Date:  2014-08-20       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.